马西文,秦明照,赵焕英,常志文,张勇,宋爱丽

• 1:河南大学附属郑州市第一人民医院内分泌老年病科
• 2:首都医科大学附属北京同仁医院
• 3:首都医科大学

摘要(Abstract)：

目的观察阿托伐他汀对糖尿病ApoE基因敲除小鼠主动脉组织中CD55、CD59表达的影响。方法 22只雄性6周龄ApoE基因敲除小鼠随机分为糖尿病动脉粥样硬化(对照)组(12只)和阿托伐他汀干预(干预)组(10只),予链脲佐菌素(55 mg.kg-1.d-1体质量)连续5次腹腔注射建立糖尿病模型,普通饲料喂养。造模成功后,干预组予阿托伐他汀(10 mg.kg-1.d-1体质量)灌胃8周。监测生化指标,测量斑块面积;采用免疫荧光和Real-time PCR技术,观察阿托伐他汀干预后小鼠主动脉组织中CD55和CD59的表达变化。结果与对照组相比,阿托伐他汀干预后体质量增加,血糖和血脂无变化,血清淀粉样蛋白-A[(5.9±3.2)μg/mL vs.(3.8±1.6)μg/mL,P>0.05]和动脉粥样硬化病变面积呈减少趋势[(264046.4±88374.97)μm2vs.(218752.4±87927.16)μm2,P>0.05]。免疫荧光显示,阿托伐他汀干预后小鼠主动脉组织中CD55和CD59表达较对照组增强。Real-time PCR结果显示,与对照组比较,阿托伐他汀干预后CD55和CD59 mRNA相对表达量无明显变化(0.55±0.2 vs.0.43±0.11,0.76±0.36 vs.0.55±0.13,P均>0.05)。结论独立于调脂作用之外,阿托伐他汀可能具有上调CD55和CD59蛋白表达的作用。

关键词(KeyWords)： 糖尿病;动脉粥样硬化;CD55;CD59;阿托伐他汀;ApoE

Abstract:

Keywords:

基金项目(Foundation): 郑州市科技发展计划项目(编号:112PPTSF306-2);; 郑州市医学博士创业基金;; 河南省卫生科技创新型人才工程专项经费资助;; 郑州市创新型科技人才队伍建设工程项目

作者(Author): 马西文,秦明照,赵焕英,常志文,张勇,宋爱丽

参考文献(References)：

• [1]Davignon J.Beneficial cardiovascular pleiotropic effects of st-atins[J].Circulation,2004,109(23 suppl 1):III39-43.
• [2]Mason JC,Ahmed Z,Mankoff R,et al.Statin-induced ex-pression of decay-accelerating factor protects vascular endothe-lium against complement-mediated injury[J].Circ Res,2002,91:696-703.
• [3]刘永铭,何津春,杨京港,等.阿托伐他汀对高脂血症患者补体调节蛋白CD55、CD59表达的影响[J].中华心血管病杂志,2005,33(12):1 075-1 079.
• [4]Fujii A,Allen TJ,Nestel PJ.A 1,3-diacylglycerol-rich oil in-duces less atherosclerosis and lowers plasma cholesterol in dia-betic apoE-deficient mice[J].Atherosclerosis,2007,193:55-61.
• [5]Zuccollo A,Shi C,Mastroianni R,et al.The thromboxane A2receptor antagonist S18886 prevents enhanced atherogenesiscaused by diabetes mellitus[J].Circulation,2005,112:3 001-3008.
• [6]Pospisilova N,Semecky V,Jamborova G,et al.Endolin ex-pression in hyper-cholesterolemia and after atorvastatin treat-ment in apoE-deficient mice[J].J Pharm Sci,2006,9(3):388-397.
• [7]赵全明,颜东,宋爱丽,等.罗格列酮对ApoE基因敲除小鼠动脉粥样硬化的影响[J].中华心血管病杂志,2005,33(5):399-404.
• [8]Ma Xiwen,Chang Zhiwen,Qin Mingzhao,et al.Decreased e-xpression of complement regulatory proteins,CD55 and CD59,on peripheral blood leucocytes in patients with type 2 diabetesand macrovascular diseases[J].CMJ,2009,122:2 123-2 128.
• [9]Nakashima Y,Plump AS,Raines EW,et al.ApoE-deficientmice develop lesions of all phases of atherosclerosis throughoutthe arterial tree[J].Arterioscler Thromb,1994,141:133-140.
• [10]Park L,Raman KG,Lee KJ,et al.Suppression of acceler-ated diabetic atherosclerosis by the soluble receptor for ad-vanced glycation endproducts[J].Nat Med,1998,4:1 025-1031.
• [11]Yasojima K,Schwab C,McGeer EG,et al.Complement co-mponents,but not complement inhibitors,are upregulated inatherosclerotic plaques[J].Arterioscler Thromb Vasc Biol,2001,21:1214-1219.